Sanofi Closed Sale Of 50% Stake In Opella To CD&R For €10B
Novartis To Buy Regulus Therapeutics For $7.00/Shr In Cash, With Potential To Receive Addl $7.00/Shr In Cash Through Contingent Value Right, For Total Equity Value Of Up To About $1.7B
GSK Posts Q1 Beat Thanks to Specialty Medicines
GSK Affirms Its FY25 Guidance And Expects Its Turnover To Increase Between 3%-5% And Core Operating Profit To Increase Between 6%-8%. Core EPS Is Expected To Increase Between 6%-8%
GSK Q1 Adj. EPS $1.13 Beats $1.04 Estimate, Sales $9.46B Beat $7.46B Estimate
Dow Surges 300 Points Amid Trade Deal Hopes: Greed Index Remains In 'Fear' Zone